Clinical Trial Search

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year

Primary: Local Control — 13; 23; 2; 1 participants

Primary: Time to Neurocognitive Failure — 68.2; 59.3 percentage of participants — p=0.029

Primary: Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT — 3.0; 3.7 Months — p=<0.0001

Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001

Primary: Overall Response Rate — 71 % of pts w/complete or partial response

Primary: Activity of Vemurafenib in Untreated Brain Metastases

Primary: Quantitative Measurement of [18F]FPIA Uptake Within the Cerebral Metastases of Treatment naïve Patients. — 1.54; 1.47; 1.48 SUV_max (kBq/L/kBq/g)

Primary: Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension — 27 ml/min — p=0.0276

Primary: Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall) at 24 Weeks — 0; -0.9 units on a scale — p=0.059

Primary: Percentage of Participants With Distant Brain Failure (DBF) at One Year — 37 percentage of participants

Primary: Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Vorinostat and Radiotherapy in Patients With Brain Metastases. — 300 mg

Primary: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) — 88.9 percentage of participants

Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844